Table 1. HFMD and CNS diseases induced by different clinical isolates of EV71 and CVA16 in hSCARB2-Tg mice.
| Virus strains (genotype) | HFMD | CNS | ||||
| Limb paralysis (%) | Death (%) | |||||
| Tg | Non-Tg | Tg | Non-Tg | Tg | Non-Tg | |
| E59(B4) | 100(16/16) | 57.1(4/7) | 18.8(3/16) | 14.2(1/7) | 0(0/16) | 0(0/7) |
| N-2838(B5) | 100(9/9) | 75(6/8) | 44.4(4/9) | 12.5(1/8) | 0(0/9) | 0(0/8) |
| 5746(C2) | #Nd | #Nd | 100(10/10) | 57.1(4/7) | 100(10/10) | 0(0/7) |
| N-3340(C4) | Nd | Nd | 100(7/7) | 100(7/7) | 100(7/7) | 0(0/7) |
| CVA16 | Nd | Nd | 100(8/8) | 100(6/6) | 100(8/8) | 100(6/6) |
1-d-old Tg and non-Tg mice were injected s.c. with 1×107 pfu of E59 or N-2838, and 7-d-old Tg and non-Tg mice were injected with 3×104 pfu of 5746 or N-3340 EV71 strains or 3×105 pfu of CVA16. The signs of HFMD and CNS diseases were monitored. The incidence of severe disease (the number of animals scored >3) on day 10 post challenge was shown as the percentage rate (number of mice with disease per total number of tested mice).
#
disease was not detected.